Andreessen Horowitz
Listed as “Amber”
- First observed:
- 29 Oct 2026
- Investment announced:
- Date not recorded
Amber Bio develops gene editing technology for potential medical treatments.
Amber Bio is a biotechnology company developing gene editing approaches using multi-kilobase edits for patient populations with limited treatment options.
Bio + Health
Category source ↗Checked
Some source history is available; coverage remains limited.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
Listed as “Amber”
No dated funding or investment events are recorded yet. Initial portfolio listings establish the starting baseline and earn no points.